NCT03735628 - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions

Non-small Cell Lung Cancer (NSCLC)Head and Neck Squamous Cell Carcinoma (HNSCC)Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Copanlisib

Copanlisib: lyophilisate for reconstitution and further dilution for infusion

DRUG

Nivolumab

Nivolumab: concentrate for solution for infusion

Trial Locations (6)

Rhode Island Hospital, Providence

Gabrail Cancer Center, Canton

Rocky Mountain Cancer Centers / Denver, CO, Denver

Orthopaedic Institute for Children, Los Angeles

Tower Hematology/Oncology Medical Group, Beverly Hills

Princess Margaret Cancer Centre, Toronto